CD8A and neoplasm: Our results are consistent with several studies demonstrating that fusion with Ii improves antigen presentation and is able to accelerate, broaden and increase CD8+ T cell responses against pathogens [41–44] and tumour self-antigens following immunization with adenovirus-vectored vaccines [21, 22].